Trimikos is indicated in full-term newborns, infants, infants, children and adolescents from 0 to 17 years. Trimikos is used in the treatment of mucosal candidiasis (oropharyngeal and oesophageal), invasive candidiasis, cryptococcal meningitis and in the prophylaxis of candidiasis in immunocompromised patients. Trimikos can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with a high risk of relapse. Therapy can be instituted before culture or other laboratory test results are known, but when results become available, anti-infective therapy should be adjusted accordingly.
The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.